Oncolytics reports results of immuno-oncolytic virus with CAR T therapy

By The Science Advisory Board staff writers

February 23, 2021 -- Oncolytics Biotech is reporting new data from a preclinical study where pelareorep, its proprietary immuno-oncolytic virus and chimeric antigen receptor (CAR) T-cell combination therapy for solid tumors, vastly improved outcomes compared to the use of an oncolytic vesicular stomatitis virus (VSV) to weaken tumors.

Pelareorep is a nonpathogenic, proprietary isolate of the unmodified reovirus. The product induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers, according to the firm.

The published results, developed in collaboration with researchers from the Mayo Clinic and Duke University, show that loading CAR T-cells with pelareorep improved the persistence and efficacy of CAR T-cells in mouse models. The efficacy was further boosted with a single intravenous dose of pelareorep, which generated highly persistent CAR T-cells and inhibited recurrent tumor growth.

The company is exploring further development of pelareorep as an enabling technology for CAR T-cells and additional immunotherapies that require immune effector cell infiltration in solid tumors.

Copyright © 2021 scienceboard.net

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter